Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

104 trials with published results (26%)

Research Maturity

238 completed trials (60% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

5.1%

20 terminated out of 395 trials

Success Rate

92.2%

+5.7% vs benchmark

Late-Stage Pipeline

25%

97 trials in Phase 3/4

Results Transparency

44%

104 of 238 completed with results

Key Signals

104 with results92% success20 terminated

Data Visualizations

Phase Distribution

231Total
Not Applicable (71)
Early P 1 (3)
P 1 (17)
P 2 (43)
P 3 (67)
P 4 (30)

Trial Status

Completed238
Recruiting47
Unknown40
Active Not Recruiting22
Terminated20
Not Yet Recruiting12

Trial Success Rate

92.2%

Benchmark: 86.5%

Based on 238 completed trials

Clinical Trials (395)

Showing 20 of 20 trials
NCT03816345Phase 1Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT06671496Phase 3RecruitingPrimary

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

NCT06671483Phase 3RecruitingPrimary

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT05616871CompletedPrimary

An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis

NCT07406035Phase 2RecruitingPrimary

A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

NCT03896581Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT03895203Phase 3CompletedPrimary

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT07718815Not ApplicableRecruitingPrimary

HLA B Leader in Patients With Psoriatic Arthritis

NCT07180537Not ApplicableRecruiting

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

NCT06506916Phase 3Active Not Recruiting

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06888193Phase 1Recruiting

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06382051Not ApplicableRecruiting

Modifying PEST for Psoriatic Arthritis Screening

NCT05772325Not ApplicableActive Not Recruiting

The Effect of Brief Versus Individually Tailored Dietary Advice on Change in Lipids, Blood Pressure, and Diet in Patients With Inflammatory Joint Disease

NCT04009499Phase 3CompletedPrimary

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT06624228Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

NCT07290036Phase 1RecruitingPrimary

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

NCT07486960Phase 2RecruitingPrimary

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

NCT04180904Not ApplicableCompletedPrimary

Diet Interventions in Psoriatic Arthritis

NCT03531073CompletedPrimary

Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis

NCT07286058Phase 3RecruitingPrimary

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Scroll to load more

Research Network

Activity Timeline